Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab-Based Maintenance in Relapsed Multiple Myeloma After Salvage ASCT
NCT03622775Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2019
- Primary completion
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Complete Remission Rate at 9 months. Started Apr 2019; status: terminated.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03622775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03622775.